Moleac holds two educational symposia on the management of Traumatic Brain Injury
Moleac holds two educational symposia on the management of Traumatic Brain Injury March 2019 Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic Brain Injury (TBI) recovery. In these symposia, the speakers emphasized on the global burden...
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset More subjects on NeuroAiD™ improved to functional independence compared to placebo among...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research and development of new medicines for central nervous...
NeuroAiD at ASEAN Neurological Association
NeuroAiD at ASEAN Neurological Association Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) & 39th Annual Convention of Philippine Neurological Association (PNA), in Manila, Philippines from 21 to 24 November. Prof. N...
